Wells Fargo raised the firm’s price target on Merit Medical (MMSI) to $108 from $106 and keeps an Overweight rating on the shares. The firm notes the company has announced it acquired hemostasis products, StatSeal and WoundSeal, from BioLife for $120M in cash or about 6.7-times forward year sales. The deal is expected to add $10M-$11M in revenue and be a penny dilutive to EPS in FY25.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Acquires Biolife Delaware for $120 Million
- Merit Medical’s Strategic Acquisition of Biolife Delaware: A Long-Term Growth Catalyst
- Merit Medical adjusts FY25 EPS view to $3.28-$3.41 from $3.29-$3.42
- Merit Medical acquires Biolife Delaware
- Merit Medical Systems Shareholders Approve Key Proposals